Arvinas Is A Clinical Stage Biotechnology Company Based In New Havenconnecticutfounded In 2013 By Drcraig Crewsthe Company Specializes In Developing Protaca Proteolysis Targeting Chimeratherapeuticsa New Class Of Drugs Aimed At Degrading Disease Causing Proteinsthis Innovative Approach Targets Previouslyundruggableproteinsparticularly In Oncology And Neurodegenerative Diseasesby Utilizing The Cell S Natural Protein Degradation Mechanisms Arvinas Is Advancing Several Promising Candidates In Its Pipelineincluding Arv 471Which Targets The Estrogen Receptor For Breast Cancer And Is Currently In Phase 3 Trialsand Arv 110Aimed At The Androgen Receptor For Prostate Cancerin Phase 2 Trialsthe Company Collaborates With Major Biopharmaceutical Firms Like Pfizer And Bayer To Enhance Its Research And Development Effortsarvinas Is Committed To Cultivating New Treatments Through Targeted Protein Degradationemphasizing Scientific Rigor And Collaboration To Bring Innovative Therapies To Patients With Life Threatening Diseases
Bio International Convention 2025
United States
16 Jun 2025
635
| Company Name | Arvinas Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
